Onco Actu du 18 janvier 2016

	1. Biologie
LAUNCHED: VHIO´s Special Symposium on Towards Predictive Cancer Models, 26 – 27 May, 2016 [Vall d'Hebron Institute Oncology] Our focus will center firmly on empowering current predictive cancer models by pooling knowledge, sharing perspectives and moving together to more swiftly, and more cost-effectively advance cancer precision medicine.
	2. Etiologie
Why scented candles could cause cancer [The Telegraph] A study carried out by Professor Alastair Lewis of the National Centre for Atmospheric Science at the University of York found that an ingredient commonly used to give candles their scent mutates into formaldehyde upon contact with the air.
	3.1 Tabac
Researchers criticise study claiming e-cigarettes may lower chances of successfully quitting [Cancer Research UK] “We should be very cautious about assuming that this review tells us that e-cigarettes don't help smokers quit. Other evidence suggests they do - and this is particularly relevant for the UK where smoking rates have continued to decrease as e-cigarette use has increased.”
Children are increasingly using e-cigarettes amid fears they are being lured by sweet-flavoured versions, study shows [The Telegraph] Professor Kevin Fenton, director for health and wellbeing at Public Health England, said the PHE was "cautiously optimistic" about the results that e-cigarette advertising does not make smoking tobacco more attractive.
	3.3 Prévention - Vaccins
A Need to Increase Awareness of HPV Vaccines and Cervical Cancer Prevention [CANCER RESEARCH Catalyst] “We are currently missing many opportunities to protect today’s young people from future HPV-related cancers. Helping providers communicate about the HPV vaccine effectively is a promising strategy for getting more adolescents vaccinated.”
	4. Dépistage, diagnostic et pronostic
Committee recommends upgrades to NHS bowel and cervical screening programmes [Cancer Research UK] The announcement, based on independent expert reviews, recommends that an updated test be introduced to the bowel screening programme, and for cervical screening to switch the order of the tests carried out on samples.
	4.9 Dép., diag. & prono. - Sein
The Problem With The New Breast Cancer Screening Recommendations [Forbes] The USPSTF has declared itself the only voice supported by science and directed by data, but its closed-door discussions should not be the final say on this disease or how hard and how early we try to fight it.
	5.10 Traitements - Essais
Well: Living With Cancer: A Broken Covenant With Patients [NY Times] The scandal proliferates. Apparently the F.D.A. can levy fines up to $10,000 a day per trial for late reporting; however, it has never penalized any institution or company for failing to post on ClinicalTrials.gov.
	5.2 Pharma
Two drug makers engage in a murky battle over the use of the Merck name [STAT] What’s in a name?Plenty, especially if you happen to run a company called Merck. In fact, there are two drug makers with that moniker. One is based in the United States and the other is headquartered in Germany, but is formally known as Merck KGgA. And not surprisingly, they are warring over use of the name — again.
	5.3 Traitements - FDA, EMA,...
FDA delays decision on Heron's nausea drug [Reuters] Heron Therapeutics Inc said the U.S. Food and Drug Administration had postponed a decision on its injectable drug to treat chemotherapy-induced nausea. The FDA is now expected to decide on Sustol by late February instead of the earlier deadline of Sunday.
	5.4 Traitements - Economie
Syros raises $40M to get its leukemia drug into Phase II [FierceBiotech] With its new funds, Syros is blueprinting a Phase II trial for SY-1425, targeting acute myelogenous leukemia and myelodysplastic syndrome patients who have certain genetic mutations.
	5.5 ASCO
Inaugural Symposium Highlights Notable Research in Survivorship Care [ASCO] These select abstracts, highlighted in addition to the official meeting Press Program, examine psychosocial and weight loss interventions for cancer survivors, weight patterns and cognitive function in survivors, and oncologist and primary care physician attitudes toward follow-up care practices.
Everolimus Slows Growth of Neuroendocrine Tumors [ASCO] Researchers report the results of a new analysis from a phase III trial of patients with neuroendocrine tumors that begin in the gastrointestinal (GI) tract or have an unknown origin. Compared to placebo, everolimus was associated with a six- to eight-month longer time period before the cancer worsened.
New Targeted Hormone-Radiation Treatment Slows Growth of Midgut Neuroendocrine Tumors [ASCO] According to the authors, this is the first prospective, randomized trial to evaluate the efficacy of 177Lutetium-DOTATATE in patients with advanced midgut neuroendocrine tumors. All 230 trial participants had advanced tumors that worsened despite first-line somatostatin analog therapy. The patients were randomly assigned to treatment with 177Lutetium-DOTATATE or high-dose octreotide LAR.
New Regimen for Locally Advanced Rectal Cancer as Effective but Less Toxic Than Chemoradiation [ASCO] The study enrolled 515 patients with locally advanced rectal cancer (stage cT3 or cT4). The patients were assigned to chemoradiation or the experimental (short-course radiation) regimen.
	6. Lutte contre les cancers
Grand Challenge four: how do you tell the lethal cancers from the non-lethal ones? [Cancer Research UK] So our fourth Grand Challenge is all about delving deeper into cancer’s biology to solve two of the most important mysteries in medicine – how to tell the difference between the cancers that can kill and the slow-growing forms of the disease that don’t, and how to track down the cancers that stay hidden until it’s too late.
	6.10 Politiques
Moonshot, They Say [In the Pipeline] Gitlin’s right: we don’t need another big, flashy initiative, no matter how nice it sounds. We need steady, sustained work in this area, which means steady funding, and not yanking people around to serve on committees to see how to get some of the fast cash, which will disappear, anyway.
Penn cancer center will help launch Joe Biden 'moonshot' [STAT] Personal connections aside, it’s the center’s work with immunotherapy that caught Biden’s attention.
Biden to lead federal cancer 'moonshot' task force [STAT] A major theme of the roundtable discussion that Biden led with a dozen researchers, which lasted more than an hour, was his desire to bridge gaps between different research institutions, as well as the pharmaceutical industry.
ASCO Official Participates in Vice President’s “Moonshot” Launch [ASCO] In meetings and interactions with Biden's office leading up today’s launch, ASCO stressed the need to widely implement “big data” initiatives, such as ASCO’s CancerLinQ rapid-learning system, for the immediate benefit of current patients and long-term benefit of patients around the world for generations to come.
	6.7 DMP, Big Data & applis
NIH’s big cancer database coming soon [Washington Post] When it launches this summer, the Genomic Data Commons will be able to hold data from as many as 50,000 patients and clinical trial participants, including genomic analysis of their cancers, the treatments used, their responses and outcomes, Lowy said. The information would come not just from NCI clinical trials but from other research as well.